Work group of DZL researcher identifies target molecule for the treatment of chronic obstructive pulmonary disease (COPD).
Lung cancer is the leading cause of cancer death for both men and women and accounts for almost 28% of all cancer deaths worldwide, and global incidence is increasing by ~0.5% per year. Lung cancer is often fatal, with a 5-year survival rate of ~14%, primarily owing to a lack of early detection and a lack of effective therapies in later states.
In a new project, scientists at the German Center for Lung Research (DZL) investigate the impact of e-cigarette vapor on lung health. This interdisciplinary approach combines various projects of all five sites. The project is financed by the prize money of the International Balzan Prize Foundation and additional DZL funds. The DZL was awarded the Balzan Prize in November 2019 for its influential work in the field of pathophysiology of respiration.
A top global priority is to find agents that can stop the severe course of COVID-19 infection and consequently increase the chances of patient survival as rapidly as possible. Specific tests have shown that there are some promising drugs available, which have efficacy against the new coronavirus and have already been approved for the treatment of other diseases such as HIV and malaria. The World Health Organisation (WHO) has selected four particularly promising agents or agent combos for testing in a clinical trial programme that is being conducted across several countries. The DZIF and DZL have assumed the role of coordinating this Solidarity Trial in Germany. The trial is being supported by all German Centres for Health Research (DZG) and is being funded by the BMBF (Federal Ministry of Education and Research).
The German Center for Lung Research (DZL) is an association of the leading university and non-university institutions dedicated to lung research in Germany. Using translational research methods, the DZL seeks to jointly develop new approaches for the prevention, diagnosis and therapy of serious lung diseases including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, diffuse parenchymal lung disease (DPLD), endstage lung disease, lung cancer, pneumonia and acute lung injury, and pulmonary hypertension.